Side effects of ixazomib

Ninlaro (ixazomib) is an oral anticancer drug used to treat multiple myeloma. Take orally once weekly during the first 3 weeks of a 4-week treatment cycle. This drug is usually given as triple therapy with lenalidomide (Revlimid) and dexamethasone. But this treatment is only available to people who have already tried other drugs to treat multiple myeloma.

The most common side effects of ixazomib (occurring in more than one in five people) when taken with lenalidomide and dexamethasone are diarrhea, constipation, thrombocytopenia (low platelet count), neutropenia, peripheral neuropathy (damage to the nerves in the hands and feet, causing tingling or numbness), nausea (feeling uncomfortable), peripheral edema (swelling, especially in the ankles and feet), vomiting, and nose and throat infections. Similar side effects were seen when lenalidomide and dexamethasone were used without ixazomib.

So far, ixazomib has been launched in the domestic market and has also been included in the medical insurance reimbursement system. The domestic specification of this drug is 4mg*3 tablets. After medical insurance reimbursement, patients may only need to pay about 4,000 yuan, but the specific amount will vary depending on regional medical insurance policies. On the other hand, patients can also consider purchasing the overseas generic version of Ixazomib produced by Lucius Pharmaceuticals in Laos, which has received market access from the Ministry of Health of Laos. The price of the same specifications is only about 900 yuan, which effectively reduces the financial burden of patients. Before taking this medicine, patients are advised to read the instructions for use in detail and consult a doctor or pharmacist for professional guidance.